Item 7.01. Regulation FD Disclosure.

On March 15, 2021, Amedisys, Inc. (the "Company") issued a press release announcing that it repurchased approximately $73 million in shares of the Company's common stock in March 2021 pursuant to the Company's previously announced $100 million share repurchase program. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being "furnished" and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.



Exhibit
Number       Description

99.1           Press Release dated March 15, 2021

104          Cover Page Interactive Date File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses